167 related articles for article (PubMed ID: 38390203)
41. The limited value of the desmopressin test in the diagnostic approach to Cushing's syndrome.
Terzolo M; Reimondo G; Alì A; Borretta G; Cesario F; Pia A; Paccotti P; Angeli A
Clin Endocrinol (Oxf); 2001 May; 54(5):609-16. PubMed ID: 11380491
[TBL] [Abstract][Full Text] [Related]
42. Cushing's disease.
De Martin M; Pecori Giraldi F; Cavagnini F
Pituitary; 2006; 9(4):279-87. PubMed ID: 17077950
[TBL] [Abstract][Full Text] [Related]
43. The expression of glucocorticoid and mineralocorticoid receptors in pituitary tumors causing Cushing's disease and silent corticotroph tumors.
Kober P; Rusetska N; Mossakowska BJ; Maksymowicz M; Pękul M; Zieliński G; Styk A; Kunicki J; Działach Ł; Witek P; Bujko M
Front Endocrinol (Lausanne); 2023; 14():1124646. PubMed ID: 37065760
[TBL] [Abstract][Full Text] [Related]
44. Adrenocorticotropin and cortisol hyperresponsiveness to hexarelin in patients with Cushing's disease bearing a pituitary microadenoma, but not in those with macroadenoma.
Arvat E; Giordano R; Ramunni J; Arnaldi G; Colao A; Deghenghi R; Lombardi G; Mantero F; Camanni F; Ghigo E
J Clin Endocrinol Metab; 1998 Dec; 83(12):4207-11. PubMed ID: 9851753
[TBL] [Abstract][Full Text] [Related]
45. Effects of repetitive administration of corticotropin-releasing hormone combined with lysine vasopressin on plasma adrenocorticotropin and cortisol levels in secondary adrenocortical insufficiency.
Fukata J; Usui T; Tsukada T; Nakai Y; Koh T; Ishihara T; Tanaka I; Uchida K; Yoshimasa T; Nakano R
J Clin Endocrinol Metab; 1990 Dec; 71(6):1624-31. PubMed ID: 2172283
[TBL] [Abstract][Full Text] [Related]
46. Somatostatin and somatostatin receptors in Cushing's disease.
Hofland LJ
Mol Cell Endocrinol; 2008 May; 286(1-2):199-205. PubMed ID: 18221833
[TBL] [Abstract][Full Text] [Related]
47. Growth hormone and prolactin responses to corticotrophin-releasing-hormone in patients with Cushing's disease: a paracrine action of the adenomatous corticotrophic cells?
Loli P; Boccardi E; Branca V; Bramerio M; Barberis M; Losa M; Terreni MT; Lodrini S; Pollo B; Vignati F
Clin Endocrinol (Oxf); 1998 Oct; 49(4):433-9. PubMed ID: 9876339
[TBL] [Abstract][Full Text] [Related]
48. Acquired prolactin deficiency (APD) after treatment for Cushing's disease is a reliable marker of irreversible severe GHD but does not reflect disease status.
Mukherjee A; Murray RD; Teasdale GM; Shalet SM
Clin Endocrinol (Oxf); 2004 Apr; 60(4):476-83. PubMed ID: 15049963
[TBL] [Abstract][Full Text] [Related]
49. Adrenocorticotropin- and cortisol-releasing effect of hexarelin, a synthetic growth hormone-releasing peptide, in normal subjects and patients with Cushing's syndrome.
Ghigo E; Arvat E; Ramunni J; Colao A; Gianotti L; Deghenghi R; Lombardi G; Camanni F
J Clin Endocrinol Metab; 1997 Aug; 82(8):2439-44. PubMed ID: 9253314
[TBL] [Abstract][Full Text] [Related]
50. Cushing's syndrome: from physiological principles to diagnosis and clinical care.
Raff H; Carroll T
J Physiol; 2015 Feb; 593(3):493-506. PubMed ID: 25480800
[TBL] [Abstract][Full Text] [Related]
51. Paradoxical response to dexamethasone and spontaneous hypocortisolism in Cushing's disease.
Lila AR; Sarathi V; Bandgar TR; Shah NS
BMJ Case Rep; 2013 Jan; 2013():. PubMed ID: 23365169
[TBL] [Abstract][Full Text] [Related]
52. Adrenocorticotrophic hormone (ACTH) responsiveness to ghrelin increases after 6 months of ketoconazole use in patients with Cushing's disease: comparison with GH-releasing peptide-6 (GHRP-6).
Correa-Silva SR; Nascif SO; Molica P; Sá LB; Vieira JG; Lengyel AM
Clin Endocrinol (Oxf); 2010 Jan; 72(1):70-5. PubMed ID: 19453623
[TBL] [Abstract][Full Text] [Related]
53. Classic and recent etiologies of Cushing's syndrome: diagnosis and therapy.
Beauregard C; Dickstein G; Lacroix A
Treat Endocrinol; 2002; 1(2):79-94. PubMed ID: 15765624
[TBL] [Abstract][Full Text] [Related]
54. Preclinical Cushing's disease characterized by massive adrenal hyperplasia and hormonal changes after three years of metyrapone therapy.
Ohmori N; Nomura K; Ohmori K; Takano K
Endocr J; 2007 Jun; 54(3):391-7. PubMed ID: 17446657
[TBL] [Abstract][Full Text] [Related]
55. Macroprolactinoma associated with Cushing's disease, successfully treated with cabergoline.
T'Sjoen G; Defeyter I; Van De Saffele J; Rubens R; Vandeweghe M
J Endocrinol Invest; 2002 Feb; 25(2):172-5. PubMed ID: 11929090
[TBL] [Abstract][Full Text] [Related]
56. Benzodiazepines attenuate the pituitary-adrenal responses to corticotrophin-releasing hormone in healthy volunteers, but not in patients with Cushing's syndrome.
Korbonits M; Trainer PJ; Edwards R; Besser GM; Grossman AB
Clin Endocrinol (Oxf); 1995 Jul; 43(1):29-35. PubMed ID: 7641409
[TBL] [Abstract][Full Text] [Related]
57. A case of ruptured dissecting aneurysm 5 years after pituitary microsurgical treatment of Cushing's disease: autopsy findings in the hypothalamic-pituitary-adrenal axis.
Suzuki T; Sasano H; Murakami O; Nagura H
Endocr J; 1993 Oct; 40(5):613-8. PubMed ID: 7951528
[TBL] [Abstract][Full Text] [Related]
58. Diagnosing Cushing's disease in the context of chronic kidney disease: a case report and literature review.
Stroud A; Zhang J; McCormack A
Eur J Endocrinol; 2019 Oct; 181(4):K29-K35. PubMed ID: 31382242
[TBL] [Abstract][Full Text] [Related]
59. How early can one diagnose Cushing's disease? An early diagnosis in a case of prepubertal Cushing's disease.
Hoppmann J; Wagner IV; Junghans G; Wudy SA; Buchfelder M; Hirsch FW; Ritter L; Kiess W; Pfäffle R
J Pediatr Endocrinol Metab; 2014 Nov; 27(11-12):1043-7. PubMed ID: 25367688
[TBL] [Abstract][Full Text] [Related]
60. Amenorrhea-galactorrhea associated with Cushing's disease due to pituitary tumor.
Rodriguez S; Alger M; Forsbach G; Contreras SN; Canales ES; Zarate A
J Endocrinol Invest; 1981; 4(1):37-40. PubMed ID: 6263966
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
